

26 public awareness.—

27 (1) DEFINITIONS.—As used in this section, the term:

28 (a) "Department" means the Department of Health.

29 (b) "Health care provider" means a physician licensed
30 under chapter 458 or chapter 459 or an autonomous advanced
31 practice registered nurse registered under s. 464.0123.

32 (c) "Uterine fibroid" means a noncancerous growth of the
33 uterus that often appears during a woman's childbearing years.

34 (2) UTERINE FIBROID RESEARCH DATABASE.—

35 (a) The department shall develop and maintain an
36 electronic database consisting of information related to uterine
37 fibroids. The purpose of the database is to encourage research
38 relating to the diagnosis and treatment of uterine fibroids and
39 to ensure that women are provided with the relevant information
40 and health care necessary to prevent and treat uterine fibroids.
41 The database must include, but need not be limited to, all of
42 the following information:

43 1. Incidence and prevalence of women diagnosed with
44 uterine fibroids in the state.

45 2. Demographic attributes of women diagnosed with uterine
46 fibroids in the state.

47 3. Treatments and procedures for uterine fibroids used by
48 health care providers in the state.

49 (b) A health care provider who diagnoses or treats a woman
50 with uterine fibroids shall submit information relating to such

51 diagnosis or treatment to the department in a form and manner
 52 prescribed by department rule for inclusion in the database.
 53 Such information may be submitted along with any reports or
 54 other information that the health care provider is required to
 55 submit to the department pursuant to state law.

56 (3) UTERINE FIBROID EDUCATION OUTREACH AND PUBLIC
 57 AWARENESS.—The department shall develop and include information
 58 related to uterine fibroids in its women's health care
 59 educational materials currently made available to the public.
 60 The information must include, but need not be limited to, the
 61 following:

- 62 (a) Possible risk factors for developing uterine fibroids.
- 63 (b) Range of available treatment options that are
 64 considered alternatives to hysterectomy.

65 Section 2. For the 2022-2023 fiscal year, the sums of
 66 \$121,852 in recurring funds from the General Revenue Fund and
 67 \$681,048 in nonrecurring funds from the General Revenue Fund are
 68 appropriated to the Department of Health and one full-time
 69 equivalent position with associated salary rate of 55,212 is
 70 authorized for the purpose of implementing this act.

71 Section 3. This act shall take effect July 1, 2022.